The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.
Quiz|Articles|April 3, 2026
OncLive Weekly News Quiz (4/3/2026): Are You Caught Up on Key Updates in MCL, Cholangiocarcinoma, and More?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, varied openers, complete sentences, ending with periods).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Which of the following best reflects the findings supporting the FDA’s full approval of brexucabtagene autoleucel (brexu-cel; Tecartus) in relapsed/refractory mantle cell lymphoma?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
3
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
4
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
5